All Updates

All Updates

icon
Filter
Product updates
Biognosys launches proprietary P2 plasma enrichment method for proteomics research
Precision Medicine
May 30, 2024
This week:
Geographic expansion
Partnerships
Lemonade partners with Homesite to expand home insurance services
InsurTech: Personal Lines
Jun 14, 2024
Funding
BayaniPay raises USD 3 million in seed funding to expand payment solutions
Neobanks
Jun 14, 2024
Partnerships
Carbonfuture and Swiss Re partner for long-term carbon removal through biochar
Carbon Management Software
Jun 13, 2024
Funding
Sidekick raises GBP 8.5 million in seed and debt funding to support expansion
Retail Trading Infrastructure
Jun 13, 2024
Partnerships
Climatiq and Epicor partner to reduce CO2 emissions in supply chains
Carbon Management Software
Jun 13, 2024
Product updates
EHang's pilotless eVTOL aircraft concludes first flight launch in Saudi Arabia
Passenger eVTOL Aircraft
Jun 13, 2024
Partnerships
Skyports partners with Unified Aviation to accelerate global network release
Passenger eVTOL Aircraft
Jun 13, 2024
Industry news
Partnerships
USSF chooses Blue Origin, SpaceX, and ULA for ~USD 5.6 billion Pentagon launch contracts
Space Travel and Exploration Tech
Jun 13, 2024
Funding
AnyCreek raises USD 1.8 million in seed funding to enhance platform and expand into new markets
Travel Tech
Jun 13, 2024
Funding
Zeta Labs raises USD 2.9 million in pre-seed funding to develop autonomous AI agent
Generative AI Applications
Jun 13, 2024
Precision Medicine

Precision Medicine

May 30, 2024

Biognosys launches proprietary P2 plasma enrichment method for proteomics research

Product updates

  • Biognosys has launched its proprietary P2 Plasma Enrichment method, which is a single-well, single particle-type enrichment designed to enhance the throughput in plasma proteomics research in human and animal-model clinical studies. The technical and performance details are planned to be presented at the American Society of Mass Spectrometry (ASMS) Annual Conference which will be held on June 3, 2024.

  • The product is designed to increase the depth and throughput of plasma proteomics by stabilizing the labile protein corona formed around plasma particles. According to the company, in a previously published five-cancer plasma sample set, the novel method has achieved a proteome coverage of 7,000 proteins, demonstrating high enrichment of low-abundant proteins and high throughput on Bruker timsTOF HT mass spectrometers. 

  • Switzerland-based Biognosys is a biotechnology company specializing in next-generation proteomics. The company’s platform-based product offerings include the True Discovery integrated proteomics drug development solution powered by its patented Hyper Reaction Monitoring (HRM) mass spectrometry, True Target, which identifies targets and de-risks the drug development process, as well as TrueSignature, which provides customizable proteomics panels for pharmacodynamic readouts and precise clinical biomarker monitoring.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.